blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2231121

EP2231121 - PHARMACEUTICAL COMPOSITIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.06.2012
Database last updated on 15.07.2024
Most recent event   Tooltip04.10.2013Lapse of the patent in a contracting state
New state(s): HU		published on 06.11.2013  [2013/45]
Applicant(s)For all designated states
KARO BIO AB
Novum
141 57 Huddinge / SE
[2010/39]
Inventor(s)01 / ANDERSSON, Carl-Magnus
Ferievägen 3
S-245 64 Hjärup / SE
02 / QVARNSTRÖM, Johanna
Fyrfatsvägen 39
S-141 59 Huddinge / SE
03 / BERGGREN, Jonas
Salagatan 42A
S-753 26 Uppsala / SE
04 / NILSSON, Marita
Storkärrsvägen 26
S-147 71 Grödinge / SE
 [2010/39]
Representative(s)Carter, Caroline Mercedes, et al
Abel & Imray 20 Red Lion Street
London WC1R 4PQ / GB
[2010/39]
Application number, filing date08863025.615.12.2008
[2010/39]
WO2008EP10636
Priority number, dateGB2007002447814.12.2007         Original published format: GB 0724478
[2010/39]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009077147
Date:25.06.2009
Language:EN
[2009/26]
Type: A2 Application without search report 
No.:EP2231121
Date:29.09.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 25.06.2009 takes the place of the publication of the European patent application.
[2010/39]
Type: B1 Patent specification 
No.:EP2231121
Date:03.08.2011
Language:EN
[2011/31]
Search report(s)International search report - published on:EP25.02.2010
ClassificationIPC:A61K9/16, A61K9/14, A61K9/20, A61K9/28, A61K31/00
[2010/39]
CPC:
A61K9/1652 (EP,US); A61K31/192 (EP,US); A61K45/06 (EP,US);
A61K9/14 (EP,US); A61K9/143 (EP,US); A61K9/1611 (EP,US);
A61K9/1694 (EP,US); A61K9/2009 (EP,US); A61K9/2846 (EP,US);
A61K9/2886 (EP,US); A61P19/08 (EP); A61P19/10 (EP);
A61P25/24 (EP); A61P27/06 (EP); A61P3/04 (EP);
A61P3/06 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P5/14 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/10 (EP) (-)
C-Set:
A61K31/192, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/39]
Extension statesAL13.07.2010
BA13.07.2010
MK13.07.2010
RS13.07.2010
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN[2010/39]
English:PHARMACEUTICAL COMPOSITIONS[2010/39]
French:COMPOSITIONS PHARMACEUTIQUES[2010/39]
Entry into regional phase13.07.2010National basic fee paid 
13.07.2010Designation fee(s) paid 
13.07.2010Examination fee paid 
Examination procedure13.07.2010Examination requested  [2010/39]
02.09.2010Amendment by applicant (claims and/or description)
17.11.2010Despatch of a communication from the examining division (Time limit: M01)
20.12.2010Reply to a communication from the examining division
02.02.2011Communication of intention to grant the patent
09.06.2011Fee for grant paid
09.06.2011Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.11.2010
Opposition(s)04.05.2012No opposition filed within time limit [2012/28]
Fees paidRenewal fee
13.01.2011Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.12.201003   M06   Fee paid on   13.01.2011
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
HU03.08.2011
LT03.08.2011
LV03.08.2011
MT03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
TR03.08.2011
BG03.11.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
LU15.12.2011
MC31.12.2011
[2013/45]
Former [2013/44]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
MT03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
TR03.08.2011
BG03.11.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
LU15.12.2011
MC31.12.2011
Former [2013/29]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
MT03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
BG03.11.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
LU15.12.2011
MC31.12.2011
Former [2013/25]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
MT03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
LU15.12.2011
MC31.12.2011
Former [2013/14]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
MT03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
MC31.12.2011
Former [2012/34]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
MC31.12.2011
Former [2012/23]CY03.08.2011
CZ03.08.2011
EE03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
RO03.08.2011
SI03.08.2011
SK03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
Former [2012/21]CY03.08.2011
CZ03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
SI03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
Former [2012/13]CY03.08.2011
HR03.08.2011
LT03.08.2011
LV03.08.2011
SI03.08.2011
GR04.11.2011
IS03.12.2011
PT05.12.2011
Cited inInternational search[Y]WO0160784  (BRISTOL MYERS SQUIBB CO [US], et al) [Y] 1-21 * the whole document *;
 [Y]EP1291021  (ALTERGON SA [CH]) [Y] 1-21 * column 12, paragraph 53 - paragraph 56 *;
 [XDY]WO2007110226  (KAROBIO AB [SE], et al) [XD] 1,3,8-9,11,15-21 * tables 3.1-3.3 * [Y] 1-21;
 [I]  - BADAWY SHERIF ET AL, "Effect of processing and formulation variables on the stability of a salt of a weakly basic drug candidate", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, (20040801), vol. 9, no. 3, ISSN 1083-7450, pages 239 - 245, XP009127510 [I] 1-21 * page 243 - page 244 *

DOI:   http://dx.doi.org/10.1081/PDT-200031417
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.